

LIST OF FIGURES

FIGURE NO.	TITLE	PAGE NO.
1.1	Types of immunity	19
1.2	An overview of Immune system	19
2.2 (a)	Picture of <i>Glycyrrhiza glabra</i> plant	31
2.2 (b)	Picture of dried <i>Glycyrrhiza glabra</i> root	31
2.3 (a)	Picture of <i>Nelumbo nucifera</i> plant	50
2.3 (b)	Leaves of <i>Nelumbo nucifera</i> plant	50
2.4 (a)	Picture of <i>Prunella vulgaris</i> plant	58
2.4 (b)	Showing all parts of <i>Prunella vulgaris</i> plant	58
2.5 (a)	Picture of <i>Zizyphus jujuba</i> plant	66
2.5 (b)	Picture of dried fruits of <i>Zizyphus jujuba</i>	66
4.1(a)	Photograph of <i>Glycyrrhiza glabra</i>	104
4.1(b)	Dried roots of <i>Glycyrrhiza glabra</i>	104
4.2(a)	Fresh leaves of <i>Nelumbo nucifera</i>	104
4.2(b)	Dried leaves of <i>Nelumbo nucifera</i>	104
4.3	Transverse sections of <i>Glycyrrhiza glabra</i> roots	105
4.4	Diagnostic features for the powder microscopy of the roots of <i>Glycyrrhiza glabra</i>	106
4.5	Transverse section of <i>Nelumbo nucifera</i> leaf	106
4.6	Diagnostic features for the powder microscopy of the leaves of <i>Nelumbo nucifera</i>	107
4.7	Calibration curve of gallic acid	116
4.8 (a)	Calibaration Curve of Naringinin	118
4.8 (b)	Calibaration Curve of Quercetin	118
4.9	Comparative DPPH free radical scavenging activity	120
4.10	Calibration curve of ascorbic acid	121
4.11	Comparative phosphomolybdanum complex method	121
5.1	UV spectra of Glycyrrhizin and Betulinic acid (100µg/ml)	142
5.2	Representative HPLC chromatogram of standard Glycyrrhizin	143
5.3	Representative HPLC chromatogram of standard Betulinic acid	144
5.4	Calibration curve of Glycyrrhizin	144

5.5	Calibration curve of Betulinic acid	145
5.6	Simultaneous determination of standard glycyrrhizin and betulinic acid	145
5.7	UV spectra of Glycyrrhizin (GLY), Quercetin (QUR), Rosmarinic acid (RA) and Betulinic acid (BA)	151
5.8	Blank chromatogram at 239nm	151
5.9	Simultaneous determination of Rosmarinic acid (RA), Quercetin (Q), Glycyrrhizin (G) and betulinic acid (BA)	152
5.10	Representative chromatograms of quarterly mixture for linearity study	152
5.11	Calibration curves of Rosmarinic acid, quercetin, glycyrrhizin and betulinic acid	154
5.12	Representative chromatogram of developed polyherbal formulation	158
5.13	Image of the TLC plate before derivatization at 254nm	162
5.14	Image of the TLC plate after derivatization with 10 % AlCl ₃ at 546 nm	162
5.15 (a)	Representative HPTLC Chromatogram of Quercetin standard	163
5.15 (b)	Representative HPTLC Chromatogram of <i>N. nucifera</i> extract	163
5.16	Spectral comparison of <i>N. nucifera</i> extract with standard quercetin	163
5.17	Representative HPTLC Chromatograms of Glycyrrhizin, Rosmarinic acid, Quercetin and betulinic acid	168
5.18 (a)	1- HPTLC chromatograms at 235nm, 2- HPTLC chromatograms at 254nm	168
5.18 (b)	Representative 3-dimensional overlaid HPTLC Chromatograms of Glycyrrhizin, Rosmarinic acid, Quercetin and betulinic acid and formulation	168
5.19	Overlain spectra of Quercetin in methanol	169
5.20	Calibration curve of quercetin	170
5.21	Overlain spectra of Glycyrrhizin in methanol	173
5.22	Calibration curve of Glycyrrhizin	173
6.1	Cyclophosphamide induced myelosuppression assay model	192

6.2	Carbon clearance test model	192
6.3	Delayed hypersensitivity response determination model	193
6.4	Humoral antibody titre determination model	193
6.5	Isolation of PMN cells from healthy human blood	195
6.6 (a)	Pareto chart	200
6.6 (b)	Half normal plot	200
6.6 (c)	Predicted Vs Actual plot	200
6.7	Main effect plots of the response EC_{50}	200
6.8	Interactions plots of the response EC_{50}	201
6.9 (a)	3D Desirability plots	201
6.9 (b)	Desirability contour plots	201
6.10	Overlay plots showing optimized area	201
6.11	Contour plots of response (R1) EC_{50}	202
6.12 (a)	Pareto chart	204
6.12 (b)	Half normal plot	204
6.12 (c)	Predicted Vs Actual plot	204
6.13	Main effect plots of the response EC_{50}	204
6.14 (a)	3D Desirability plots	205
6.14 (b)	Desirability contour plots	205
6.15	Overlay plots showing optimized area	205
6.16	Contour plots of response (R1) EC_{50}	205
6.17 (a)	Photograph of vati	206
6.17 (b)	Photograph of tablets	206
6.18	Comparison of treatment groups for cyclophosphamide induced myelosuppressive effect	215
6.19	Agglutination in different treatment groups	216
6.20	Carbon clearance assay in mice	217
6.21	DTH response in rats	217
6.22	Humoral antibody titre in rats	217
6.23	Cytotoxicity assessment of Formulation A	220
6.24	Cytotoxicity assessment of Formulation B	220
6.25	Cytotoxicity assessment of Formulation C	220
6.26	Black formazon in different treatment groups	221

6.27	Comparison of different treatment groups for NBT positive neutrophils	222
6.28	Viable (unstained) and non-viable cells (blue stained) in different treatment groups by Neutrophils candidacidal assay	224
6.29	Comparison of different treatment groups for neutrophils candidacidal assay	225
